Joseph Moore

Dr. Joseph Moore

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
LSLin Su
Lin Su
EHEllen Huang
Ellen Huang
DMDevin A. Miles
Devin A. Miles
RFReza Farjam
Reza Farjam
IMIan R. Marsh
Ian R. Marsh
Sarah Sarah Han-OhSarah Sarah Han-Oh
Sarah Sarah Han-Oh
Purpose: A single treatment planning system (TPS) model for matched linacs provides flexible clinical workflows from patient treatment to intensity‐modulated radiation therapy (IMRT) quality assurance (QA) measurement. Since general guidelines for building a single TPS model and its validation for matched linacs are not well established, we present our RayStation photon TPS modeling strategy for matched Elekta VersaHD linacs.Method: The four linacs installed from 2013 to 2020 were matched in terms of Percent Depth Dose (PDD), profile, output factor and wedge factors for 6‐MV, 10‐MV, 15‐MV, and 6‐MV‐FFF, and maintained following TG‐142 recommendations until RayStation commissioning. The RayStation single model was built to represent all four linacs within the tolerance limits recommended by MPPG‐5.a. The comprehensive validation tests were performed for one linac following MPPG‐5.a and TG‐119 guidelines, and spot checks for the other three. Our TPS modeling/validation method was evaluated by re‐analyzing the previous 103 patient‐specific IMRT/volumetric modulated arc therapy (VMAT) QA measurements with the calculated planar doses by the single model in comparison with the analysis results using four individual Pinnacle TPS models.Results: For all energies, our single model PDDs were within 1% agreement of the four‐linac commissioning measurements. The MPPG‐5.a validation tests from 5.1 through 7.5 and all TG‐119 measurements passed within the recommended tolerance limits. The IMRT QA results (mean ± standard deviation) for RayStation single model versus Pinnacle individual models were 98.9% ± 1.3% and 98.0% ± 1.4% for 6‐MV, 99.9% ± 0.1% and 99.1% ± 1.9% for 10‐MV, and 98.2% ± 1.3% and 97.9% ± 1.8% for 6‐MV‐FFF, respectively.Conclusion: We successfully built and validated a single photon beam model in RayStation for four Elekta Linacs. The proposed new validation methods were proven to be both efficient and effective.

25 June 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SSSenthamizhchelvan Srinivasan
Senthamizhchelvan Srinivasan
JMJoseph Moore
Joseph Moore
Sarah Sarah Han-OhSarah Sarah Han-Oh
Sarah Sarah Han-Oh
Theranostics has transformed nuclear medicine from an imaging-focused discipline into a data-rich radiation medicine platform in which target expression, pharmacokinetics, tumor dose, and response can be measured in the same patient. This evolution is clinically important because radiopharmaceutical therapy (RPT) is increasingly sequenced or combined with external-beam radiotherapy (EBRT) to improve precision, efficacy, and patient outcomes while potentially reducing toxicity. A rigorous combined-modality approach requires patient-specific image quantification, absorbed-dose estimation, spatial registration to the EBRT planning geometry, explicit uncertainty handling, and a clear distinction between physical absorbed dose and biologically meaningful effect. This review summarizes the current theranostic landscape, established and emerging RPT platforms, radiobiologic differences between EBRT and RPT, and practical methods for cumulative patient dose assessment. Liver-directed 90Y radioembolization combined with focal EBRT remains the most developed model, while head and neck, prostate, meningioma, and bone-dominant strategies illustrate how post-therapy imaging and voxel-level dosimetry can guide EBRT adaptation. Across platforms, direct addition of absorbed dose in gray (Gy) is a geometric description, not automatically a biologic endpoint. Future theranostic radiation medicine should therefore be built on prospective trials with prespecified dosimetry and shared cross-modality reporting standards.

4 March 2026 in The Oncologist
Verified
Journal Article
Open access
PLPornlada Likasitwatanakul
Pornlada Likasitwatanakul
SBSteven M Blinka
Steven M Blinka
JZJabra Zarka
Jabra Zarka
GGGeorges Gebrael
Georges Gebrael
EWEmily Weg
Emily Weg
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
Background: Clival metastases are a rare and clinically aggressive manifestation of advanced prostate cancer, associated with cranial nerve palsy and poor survival. The molecular features of prostate cancers giving rise to clivus metastases remain unknown. Patients and methods: We performed a multi-center retrospective study across six institutions, identifying prostate cancer patients with radiographically confirmed clival metastases and available next-generation sequencing (NGS) data. Baseline characteristics and clinical outcomes were collected. Genomic alterations from tissue- and/or blood-based assays were aggregated at the patient level and compared with a publicly available metastatic castration-resistant prostate cancer (mCRPC) cohort (SU2C/PCF). Results: Fifty-nine patients with clival metastases contributed 87 molecular assays. More than half of patients had Gleason grade group 5 cancer and presented with de novo metastatic (M1) disease. The median interval from initial prostate cancer diagnosis to clival metastasis was 71.4 months (95% CI, 42.0-101.7), while median overall survival following clival involvement was only 15.3 months (95% CI, 6.9-22.8). Compared with the SU2C/PCF mCRPC cohort, clival metastases showed significant enrichment of BRAF and CHEK2 alterations as well as homologous recombination repair (HRR) with relative depletion of AR-related, PI3K pathway, and G2–M pathway alterations. Conclusion: Prostate cancers giving rise to clival metastases exhibit a distinct molecular profile enriched for DNA damage–repair and RAF kinase alterations, suggesting unique metastatic biology and potential therapeutic vulnerabilities.

17 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SSSenthamizhchelvan Srinivasan
Senthamizhchelvan Srinivasan
JMJoseph Moore
Joseph Moore
Sarah Sarah Han-OhSarah Sarah Han-Oh
Sarah Sarah Han-Oh
Theranostics has transformed nuclear medicine from an imaging-focused discipline into a data-rich radiation medicine platform in which target expression, pharmacokinetics, tumor dose, and response can be measured in the same patient. This critical narrative review evaluates patient-specific integration of radiopharmaceutical therapy (RPT) with external-beam radiotherapy (EBRT), with emphasis on quantitative imaging, absorbed-dose estimation, spatial registration, biological interpretation, adaptation thresholds, and reporting. We performed a targeted search of PubMed/MEDLINE, ClinicalTrials.gov, U.S. Food and Drug Administration records, professional-society guidance, and reference lists for English-language evidence available through 31 July 2026, prioritizing guidelines, regulatory documents, randomized and prospective trials, technical validation studies, and clinically informative retrospective series. Established RPT platforms are distinguished from investigational combined-modality applications and emerging or speculative technologies. Liver-directed Y-90 radioembolization combined with focal EBRT remains the most developed model, whereas head and neck, prostate, meningioma, lymphoma, and bone-dominant strategies illustrate distinct clinical geometries and levels of readiness. Across platforms, direct addition of absorbed dose in gray (Gy) is a geometric description, not automatically a biological endpoint; biologically effective dose (BED) and equivalent dose in 2-Gy fractions (EQD2) should be treated as model-based estimates with explicit assumptions. Future theranostic radiation medicine should therefore be built on prospective trials with prespecified dosimetry, uncertainty analysis, adaptation rules, and shared cross-modality reporting standards.